Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Miller

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Epilepsy Research|October 8, 2021
Dravet syndrome: A quick transition guide for the adult neurologistDanielle M Andrade, Anne T Berg, Veronica Hood, et al.
Epilepsia|November 11, 2023
Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-upHeather E Olson, Sam Amin, Nadia Bahi-Buisson, et al.
Epilepsy Research|April 26, 2019
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program resultsLinda C Laux, E Martina Bebin, Daniel Checketts, et al.
BMC Public Health|October 1, 2025
A social prescribing model for tackling the health and social inequalities of people living with severe mental illness: a protocol paperGerard Leavey, Rebecca Watterson, Grainne McAnee, et al.
BMC Public Health|December 9, 2025
Correction: A social prescribing model for tackling the health and social inequalities of people living with severe mental illness: a protocol paperGerard Leavey, Rebecca Watterson, Grainne McAnee, et al.
Epilepsia Open|May 25, 2021
Consistent safety and tolerability of Valtoco<sup>®</sup> (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety studyIan Miller, James W Wheless, Robert E Hogan, et al.
Epilepsia|August 21, 2021
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsyJames W Wheless, Ian Miller, R Edward Hogan, et al.
Epilepsia|May 4, 2021
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety studyEric B Segal, Daniel Tarquinio, Ian Miller, et al.
Epilepsia|April 20, 2022
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndromePasquale Striano, Stéphane Auvin, Abigail Collins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 10, 2024
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 StudyValentina De Giorgis, Kailash P Bhatia, Odile Boespflug-Tanguy, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Epilepsy Research|October 8, 2021
Dravet syndrome: A quick transition guide for the adult neurologistDanielle M Andrade, Anne T Berg, Veronica Hood, et al.
Epilepsia|November 11, 2023
Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-upHeather E Olson, Sam Amin, Nadia Bahi-Buisson, et al.
Epilepsy Research|April 26, 2019
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program resultsLinda C Laux, E Martina Bebin, Daniel Checketts, et al.
BMC Public Health|October 1, 2025
A social prescribing model for tackling the health and social inequalities of people living with severe mental illness: a protocol paperGerard Leavey, Rebecca Watterson, Grainne McAnee, et al.
BMC Public Health|December 9, 2025
Correction: A social prescribing model for tackling the health and social inequalities of people living with severe mental illness: a protocol paperGerard Leavey, Rebecca Watterson, Grainne McAnee, et al.
Epilepsia Open|May 25, 2021
Consistent safety and tolerability of Valtoco<sup>®</sup> (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety studyIan Miller, James W Wheless, Robert E Hogan, et al.
Epilepsia|August 21, 2021
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsyJames W Wheless, Ian Miller, R Edward Hogan, et al.
Epilepsia|May 4, 2021
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety studyEric B Segal, Daniel Tarquinio, Ian Miller, et al.
Epilepsia|April 20, 2022
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndromePasquale Striano, Stéphane Auvin, Abigail Collins, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 10, 2024
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 StudyValentina De Giorgis, Kailash P Bhatia, Odile Boespflug-Tanguy, et al.
Pageof 13